Ninety-Two Percent of Surveyed Physicians Say That, if Available, They Would Use Torezolid to Manage Their Patients’ Infections, According to New Report from Arlington Medical Resources
EXTON, Pa.--(BUSINESS WIRE)-- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that over the 2006-2010 time period, the number of methicillin-resistant Staphylococcus aureus (MRSA) patients and the number of patients treated for gram-positive infections remained relatively flat while combined usage of key MRSA therapies steadily increased. The major driver of increased usage of anti-MRSA therapies is the continued uptake of vancomycin for empiric therapy. Despite the availability of numerous MRSA treatment options—Pfizer’s Zyvox (linezolid), Cubist/Novartis’s Cubicin (daptomycin) and Theravance/Astellas’s Vibativ (telavancin)—three-quarters of surveyed infectious disease (ID) specialists report that they are using increasingly higher doses (“pushing the dose”) of vancomycin to manage MRSA infections and continue to prefer vancomycin for most infections.
The new AMR report entitled Hospital Insight Series: MRSA Infections (United States) also finds that ID specialists draw few distinctions between currently available anti-MRSA therapies with the notable exception of a majority of physicians citing linezolid as the therapy with the best efficacy in hospital-acquired pneumonia due to MRSA and use in renally impaired patients. Interestingly, few physicians selected telavancin or Pfizer’s Tygacil (tigecycline) as being better than the competition on any of the ten attributes assessed in this study.
“Despite vancomycin’s stronghold on the market, physicians report that they are increasing their usage of telavancin, daptomycin and linezolid, specifically for cSSSIs due to MRSA,” said AMR Analyst Brenda Perez-Cheeks, Ph.D. “The primary driver for increased use of telavancin is fewer formulary restrictions on the drug while increased physician comfort with daptomycin and linezolid were most frequently cited as reasons for increased use of these drugs.”
The report also finds that Forest/AstraZeneca’s recently launched Teflaro (ceftaroline) is poised for strong market uptake with 1 in 6 ID specialists reporting having already used the drug primarily for the treatment of cSSSIs. Moreover, research with ID specialists finds that Trius/Bayer’s torezolid and Durata’s dalbavancin are also likely candidates to increase competition in the MRSA market. Although only 25 percent of surveyed ID specialists reported awareness of torezolid, 92 percent indicate that if available, they would use torezolid to manage MRSA patients; many believe that torezolid will replace linezolid usage for MRSA infections. Conversely, dalbavancin had much higher awareness among ID specialists as an overwhelming majority cited outpatient antimicrobial therapy as the most appropriate use of this drug.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Resources Group
Christopher Comfort, 781-993-2597
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Hospitals Infectious Diseases Pharmaceutical General Health